• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22857 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2007     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for ischemic stroke
2007     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for hip fracture patients
2009     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for bariatric surgery
2018     Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2021     Penn Medicine Center for Evidence-based Practice (CEP) Venous irritation resulting from IV fosaprepitant
2021     NIHR Health Technology Assessment programme Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2016     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line
2019     National Institute for Health and Care Excellence (NICE) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2020     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022     National Institute for Health and Care Excellence (NICE) Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2015     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax for chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
2012     National Institute for Health and Care Excellence (NICE) Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269
2012     NIHR Health Technology Assessment programme Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib (Zelboraf) for metastatic BRAF V600 mutation positive melanoma in children and adolescents
2008     Adelaide Health Technology Assessment (AHTA) Velscope(R) for oral cancer screening
2010     Adelaide Health Technology Assessment (AHTA) Velscope for oral cancer screening
2016     NIHR Horizon Scanning Centre (NIHR HSC) Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy
2012     NIHR Horizon Scanning Centre (NIHR HSC) Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Velcalcetide for secondary hyperparathyroidism – first line
2010     HAYES, Inc. Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma
2009     NIHR Horizon Scanning Centre (NIHR HSC) Velaglucerase alfa for type 1 Gaucher's disease
2014     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Velaglucerase alfa
2012     HAYES, Inc. VeinViewer (Christie Digital Systems USA Inc.) for guiding venous access procedures in children
1998     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Vein-graft surveillance - primary research
2011     NIHR Horizon Scanning Centre (NIHR HSC) VEGF trap-eye (Eylea) for macular oedema secondary to central retinal vein occlusion - first line
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for ulcerative colitis – second or subsequent line
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 342
2015     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy. NICE technology appraisal guidance 352
2014     NIHR Health Technology Assessment programme Vedolizumab for treating moderate to severe active Crohn's disease after prior therapy [ID690]
2022     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2013     NIHR Horizon Scanning Centre (NIHR HSC) Vedolizumab for Crohn's disease – second or subsequent line
2022     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2012     NIHR Horizon Scanning Centre (NIHR HSC) VBLOC® vagal blocking therapy for obesity
2009     HAYES, Inc. VasoView HemoPro endoscopic vein harvesting system (Maquet Cardiovascular LLC) for coronary artery bypass graft (CABG)
2005     Adelaide Health Technology Assessment (AHTA) Vasotrac (R) continuous blood pressure monitoring
2003     Centre for Clinical Effectiveness (CCE) Vasospasm following subarachnoid haemorrhage: papaverine infusion, nimodipine infusion or balloon angioplasty?
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vasoprotectives: efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Vasopressin as first-line therapy for cardiac arrest: a review of the guidelines and clinical-effectiveness
2015     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review (update)
2013     Health Quality Ontario (HQO) Vasodilators for inhospital heart failure management: a rapid review
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
1989     The Swedish Council on Health Technology Assessment (SBU) Vascular surgery for arteriosclerosis in the legs
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2007     Institute for Clinical Effectiveness and Health Policy (IECS) Vascular endothelial growth factor inhibitors (pegaptanib, ranibizumab and bevacizumab) in age-related macular degeneration treatment
2004     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Vascular bipolar electrocoagulation (LigaSure (TM)) and Tissular electrocoagulation and section (TissueLink (TM)) - preliminary report
2000     University HealthSystem Consortium (UHC) Varicella-zoster
2014     New Zealand National Health Committee (NHC) Varicella and rotovirus vaccination in New Zealand - assessment reports
2020     NIHR Health Services and Delivery Research programme Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
1993     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in the frequency of surgical procedures by region in the province of Quebec - nonsystematic review
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Variations in rates of tonsillectomy, adenoidectomy and myringotomy in Quebec - nonsystematic review
2014     NIHR Health Services and Delivery Research programme Variations in outcome and costs among NHS providers for common surgical procedures: econometric analyses of routinely collected data
2017     NIHR Health Services and Delivery Research programme Variations in mortality across the week following emergency admission to hospital: linked retrospective observational analyses of hospital episode data in England, 2004/5 to 2013/14
2014     NIHR Health Services and Delivery Research programme Variation in compulsory psychiatric inpatient admission in England: a cross-sectional, multilevel analysis
2001     Health Council of the Netherlands Gezondheidsraad (GR) Variant Creutzfeldt-Jakob disease and blood transfusion - review, expert panel
2009     NIHR Health Technology Assessment programme Varenicline in the management of smoking cessation: a single technology appraisal
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Varenicline for smoking cessation in patients with psychiatric illness: a review of the risks
2007     National Institute for Health and Care Excellence (NICE) Varenicline for smoking cessation
2009     Penn Medicine Center for Evidence-based Practice (CEP) Varenicline for smoking cessation
2007     Quality Improvement Scotland (NHS QIS ) Varenicline for smoking cessation
2018     National Institute for Health and Care Excellence (NICE) Vandetanib for treating medullary thyroid cancer. NICE technology appraisal guidance 550
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer
2007     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Zactima, -6474, AZD-6474, ZD6474) for medullary thyroid cancer – locally advanced or metastatic
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vandetanib (Caprelsa) for locally advanced or metastatic differentiated thyroid cancer – second line
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin-resistant enterococci isolation and screening strategies: clinical evidence and cost-effectiveness
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Vancomycin or metronidazole for treatment of clostridium difficile infection: clinical and economic analyses
2019     National Institute for Health and Care Excellence (NICE) Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction. NICE interventional procedures guidance 653
2011     Agency for Healthcare Research and Quality (AHRQ) Values of older adults related to primary and secondary prevention
2006     Agency for Healthcare Research and Quality (AHRQ) Value of the periodic health evaluation
2007     Haute Autorite de sante (HAS) Value of mutation detection and of the activated protein C resistance assay in inherited thrombophilia
2005     Haute Autorite de sante (HAS) Value of measuring FSH and LH levels in women aged 45 or over
2007     Haute Autorite de sante (HAS) Value of mandibular advancement devices in cases of obstructive sleep apnea-syndrome
1999     Hannover Medical School, Medizinische Hochschule Hannover (MHH) Value of intravascular ultrasound (IVUS) in diagnostic and therapeutic heart catherisation in patients with coronary heart disease - an economic health technology assessment
2007     Haute Autorite de sante (HAS) Value of intensity-modulated radiation therapy
2006     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Value of intensified nursing
2007     Haute Autorite de sante (HAS) Value of extra-cranial stereotactic radiotherapy
1994     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Value of echoendoscopy in gastrointestinal disease
2014     University of York Value based commissioning of MSK Procedures: an appraisal of the evidence for the proposed policies
2023     Institute for Clinical and Economic Review (ICER) Value assessment framework
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valsartan (Diovan®)
2020     Institute for Clinical and Economic Review (ICER) Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value
2002     Centre for Clinical Effectiveness (CCE) Validity of the venous thromboembolism risk factor assessment model as described by Motykie et al (2000)
2002     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Validation: dementia in elder people - primary research
2020     NIHR Health Technology Assessment programme Validation and development of models using clinical, biochemical and ultrasound markers for predicting pre-eclampsia: an individual participant data meta-analysis
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) tablets
2011     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Valganciclovir (Valcyte®) powder for oral solution
2008     HAYES, Inc. Valerian for treatment of insomnia
2002     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Valdecoxib
2001     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vagus nerve stimulator (VNS)
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2014     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vagus nerve stimulation therapy
1998     Wessex Institute for Health Research and Development (WIHRD) Vagus nerve stimulation in epilepsy
2006     Blue Cross Blue Shield Association (BCBS) Vagus nerve stimulation for treatment-resistant depression